CXCL2 and neoplasm: To prove whether CXCL2 combined with HVJ-E treatment affects breast cancer tumor growth, we first used a 4T1 tumor-bearing mouse model that was treated intratumorally (IT) or subcutaneously (s.c.)with CXCL2 plasmid DNA (pCXCL2), HVJ-E, or pCXCL2 in combination with HVJ-E once, followed by five additional treatments of HVJ-E every other day.